#4 - BioMarin Pharmaceuticals (NASDAQ:BMRN)
BioMarin Pharmaceuticals (NASDAQ:BMRN) is an undervalued name in the biopharmaceutical sector. BioMarin Pharmaceuticals occupies the gene therapy niche which gives the company higher margins and a wider moat. The company also has several patents to help protect its pipeline drugs.
The stock is down about 3% so far in 2021 and is struggling to find direction. The culprit seems to be Roctavian, the company’s gene therapy candidate for the treatment of hemophilia A. The launch of the drug was on track for this year, but the FDA requested more information in August and that means 2022 is more a likely launch date.
For many small-cap biotech stocks, news like that would be devastating, but in the case of BioMarin the sell-off looks like an opportunity. The company has a deep pipeline including a drug for treating achondroplasia, a condition that has no approved treatments. The company has filed a New Drug Application for the drug and the FDA has an August 2021 deadline.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Read More - Current Price
- $63.44
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 16 Buy Ratings, 7 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $94.20 (48.5% Upside)
